
    
      The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow
      transplantation (HBMT) on hematological malignancies are well established.The aim of this
      prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be
      decreased with IL2 therapy post HBMT.low dose of IL-2 (40 million U/m2) will be administered
      from WBC engraftment to day 90 post haploidentical transplantation. IL-2 will be administered
      three times a week.
    
  